35results about "Radioactive preparation forms" patented technology

Liposomes encapsulating a radioisotope can be used in the treatment of cancers including, but not limited to, leptomeningeal metastases. In an embodiment, liposome encapsulating a radioisotope comprising (186Re) obisbemeda can be administered to a patient through an Ommaya reservoir. The therapies can include imaging the liposome encapsulating a radioisotopе concomitant or subsequent to administration. Longitudinal analysis of the presence of tumor cells and biomarkers can be used to inform treatment strategy.

The present invention provides a pharmaceutical composition comprising a radiolabeled complex comprising a radionuclide and a targeting moiety linked to a chelating moiety, and a stabilizer against radiolytic degradation of a radiolabeled complex comprising para-aminohippuric acid or a pharmaceutically acceptable salt or carboxylic derivative thereof. The pharmaceutical composition of the present invention is characterized by high stability of its radiolabeled complex against radiolytic degradation. The present invention also provides a method for preparing such a pharmaceutical composition, and use of para-aminohippuric acid or a pharmaceutically acceptable salt or carboxylic derivative thereof for the stabilization of the radiolabeled complex of such a pharmaceutical composition.

This invention relates to the fields of brachytherapy and radiosensitization, specifically providing a... 125 I-nano implantable particles, their preparation methods, and applications. 125 The 1-nanometer implanted particles have a core-shell structure, consisting of a particle core and particles adsorbed on the outer surface of the particle core. 125 I and the particles encapsulated in the nucleus and 125 The outer shell of the I-type photosensitizer is a covalent organic framework. This invention... 125 The core of the I-nanometer implanted particle is used to enhance the energy deposition of gamma rays and X-rays, generating more hydroxyl radicals; the shell containing a type I photosensitizer is used to absorb the energy of Auger electrons and internal conversion electrons and excite the photosensitizer to generate singlet oxygen, effectively improving the response to... 125 The efficiency of I decay energy utilization. 125 I-nano implanted particles, combined with internal radiation therapy and radiodynamic therapy, destroy tumor cell DNA and cell membranes, enhance tumor killing and induce immunogenic cell death, thereby activating anti-tumor immunity and inducing remote effects.

The present invention relates to a novel compound comprising an ester group and uses thereof and, more particularly, to a novel compound that exhibits excellent visualization ability in a tumor by using the difference in activity of esterase for each organ in the body, and to uses therefor for diagnosing or treating cancer. A novel compound of chemical Formulas 1 to 8 according to the present invention exhibits selectivity according to the difference in activity of esterase for each organ due to ester residue in a structure, and thus is extremely effective in visualizing pancreatic cancer, etc.

Disclosed herein are functionalized branched poly-lysine compounds and uses thereof, as well as delivery systems in which polymeric nanocarriers are functionalized with branched poly-lysine compounds. Also provided herein are uses of the functionalized branched poly-lysine compounds and the delivery systems for treating joint diseases such as osteoarthritis, and in delivering pharmaceutically active compounds to cartilage and subchondral bone.

The present invention relates to MOFs for use in imaging and as radiolabeled tracers. More particularly, the invention provides a particle comprising a MOF, optionally at least one targeting moiety and at least one short-lived radionuclide; a composition comprising said particle; said particle or composition for use as an imaging agent; said particle or composition for use in a method for the diagnosis of a proliferative disease; said particle or composition for use in a method for the diagnosis of a chronic inflammatory disease; and a kit comprising a particle comprising a MOF, an optional targeting moiety, and a short-lived radionuclide cation.

The present disclosure generally relates to materials, processes, generators, and / or systems, for generating radioisotope. The present disclosure also generally relates to ceramic materials comprising radioisotope suitable for use in a radioisotope generator. The present disclosure also generally relates to processes, generators and / or systems, for producing and capturing radioisotope. The present disclosure also generally relates to the preparation of radioisotope solutions for use in radiopharmacy and / or other clinical applications.

The present invention relates to a system for preparing a pharmaceutical radioactive hydrogel comprising (i) at least one hydrophilic polymer, particularly at least one polysaccharide derived from chitosan or hyaluronic acid, bearing at least one chelating group and (ii) at least one therapeutical radionuclide chelatable with said chelating group. It further relates to pharmaceutical compositions comprising said hydrophilic polymer and said therapeutical radionuclide chelated with the chelating group Rc of said hydrophilic polymer, their use for treatment of solid cancer, preferably by brachytherapy.

The present application relates to a kind of microsphere preparation methods for radionuclide, by the mixing self-assembly of metabolizable polymer and polyphenols, form stable microsphere structure in the presence of nuclide ion, realize the firm package of nuclide and daughter nuclide, form the drug carrier of stable structure, can be used for in vivo transport of nuclide ion.The microspheres formed by polymer and polyphenols are loaded with radionuclide, effectively intercept the recoil of nuclide during decay, inhibit the off-target of nuclide;Solve the problem of off-target of nuclide in radioactive targeted drug, improve treatment accuracy and safety, while ensuring that microsphere is metabolizable.

The application relates to a method for producing medical grade lead-212, including the steps of:a) producing lead-212 by radioactive decay of radium-224 in at least one first chromatography column containing a first stationary phase to which radium-224 is attached;b) eluting thus produced lead-212 from the first stationary phase;c) loading the eluate thus obtained into a second chromatography column containing a second stationary phase to attach the lead-212 to the second stationary phase;d) performing wash(es) of the second stationary phase; and thene) eluting lead-212 from the second stationary phase;and wherein:step b) includes circulating in said at least one first chromatography column an aqueous solution A1 including from 0.8 mol / L to 1.6 mol / L chloride, optionally with at most 200 mmol / L HCl; andstep d) includes circulating in the second chromatography column an aqueous solution A2 including from 0.01 mol / L to 1 mol / L chloride.

A novel targeting process and nanoparticle design is disclosed, improving delivery of drugs and other payload materials to tumors and other sites of interest. In a preferred embodiment, endothelial cells are damaged at the target site, thereby activating platelets. Nanoparticles bearing fibrinogen or other materials that bind to activated platelets are administered that also contain one or more drugs or other payload substances thereby improving payload delivery to the targeted site.

The invention discloses a mineralization modification method of protein microspheres. The method comprises the following steps: dispersing protein microspheres which are not mineralized and modified in deionized water, adding metal salt, and reacting; adding Na2CO3 into the system, and continuously reacting; and after the reaction is finished, centrifuging, collecting the precipitate and washing to obtain the mineralized protein microspheres. And carrying out nuclide labeling on the mineralized protein microspheres to obtain nuclide-labeled mineralized protein microspheres. The nuclide-labeled mineralized protein microspheres can be used in radiation therapy of cancer patients, and can better predict the distribution condition of organisms. The medicine can also be used for treating middle and advanced liver cancer patients.

Intact bacterial vesicles are highly effective for in vivo delivery of boron for radiotherapeutic purposes, as in boron neutron capture therapy. A compound comprising a boron isotope, such as boron-10 or boron-11, can be joined chemically to a fluorescent moiety to produce a molecule that can be loaded stably into bacterial vesicles, which when coated with an appropriately targeting bispecific antibody can deliver boron specifically into tumor cells in an amount enabling boron-mediated radiotherapy that eliminates tumor cells with minimal damage to adjacent normal cells.

A radiotherapy source (20, 30, 40) for treating tumors comprises a radon-impermeable flexible core (22) and a polymer coating (28, 48) on the flexible core. The polymer coating is impermeable to radium and allows radon to diffuse through it. The radiotherapy source also comprises an alpha-emitting radium radionuclide (26) in the polymer coating or between the flexible core and the polymer coating.

The application relates to the technical field of tumor diagnosis and treatment, and discloses a single-particle isotope nano-carrier as well as a preparation method and application thereof, which are used for imaging analysis of an efficient and persistent oral delivery system. By establishing a novel radioactive tracing method, the single-particle isotope nano-carrier is confirmed to be retained in the gastrointestinal tract for more than 10 hours under near single-particle resolution in real time, which is significantly better than existing oral dye tracers. The multifunctional tracing carrier developed in the application is a carrier platform for topological adhesion, long-acting gastrointestinal retention and oral drug delivery tracing, and provides an extensible technical scheme for treatment of other tissue injuries and diseases.

The invention provides a method of preparing a 89Zr-oxine complex of the formulaThe invention also provides a method of labeling a cell with the 89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the 89Zr-oxine complex to the subject.

A phototherapeutic eye apparatus implanted in the eye or located proximate the eye. The apparatus comprises a solid state beta flux source for emitting beta particles and a luminophore material that is in contact with or proximate the solid state beta flux source. The luminophore material receives the beta particles and responsive thereto emits photons that escape the phototherapeutic eye apparatus and provide illumination to interior regions of the eye.

This invention provides an Auger electron radiotherapy drug that can selectively and effectively release a sufficient amount of Auger electrons into the nuclear DNA of cancer cells, even in small amounts, thereby reducing or killing cancer cells. The Auger electron radioactive isotope has a half-life that is not too short but not too long, making it highly safe and readily available. [Solution] The Auger electron radioactive therapeutic agent is encapsulated in a stimulus-responsive liposome that accumulates in cancer tissue and / or cancer cells, such that an anthracycline derivative is released upon stimulation, in which an Auger electron-emitting radioisotope-substituted benzene ring-containing group or radioisotope-substituted alkyl group is covalently bonded to the keto or amino group of anthracyclines selected from doxorubicin or daunorubicin and their reduced forms or alkoxy group-substituted forms thereof, is a stimulus-responsive liposome, or is bound to an antibody, oligopeptide, or antigen that accumulates in cancer tissue and / or cancer cells via a stimulus-responsive linker.

The present invention relates to compositions and methods for effective delivery of a therapeutic agent to a subject using a delivery vehicle comprising a domain to evade the subject's immune response. In some embodiments, the present invention relates to compositions and methods for targeted delivery of a therapeutic agent to a subject using a delivery vehicle comprising a domain to evade the subject's immune response and a domain for targeting a specific cell type. The invention also relates to methods of use of the compositions of the invention for the treatment of diseases and disorders, including the treatment of diseases and disorders in subjects having an inflammatory or autoimmune disease or disorder.

Custom radioactive seed carriers are fabricated pre-operatively and / or intra-operatively to more precisely match carrier specification of a radiation treatment plan for a particular patient. One or more carrier specification component, such as a 3D printer, injection molding system, machining component, or bioprinter, may be utilized to create the custom carrier.

The present invention provides a composition comprising: —at least one gel-forming hydrophobic carbohydrate ester or an analogue thereof based on mono-, di-, and tri-saccharides, or mixtures thereof; —at least one polymer; and —at least one solvent being mixable with water; wherein the composition is a ECell being a hydrophobic gel-depot having the ability to take up water by means of said at least one solvent being mixable with water and having the ability to self-expand by formation of water pores, channels, and / or cavities.

The embodiments of the present invention disclose a conjugate compound of formula X-J-MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof, preferably the invention relates to radiopharmaceutical compositions of 99mTc. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.

A drug delivery device includes a lumen unit to form an internal channel and an external channel, a gas unit to supply a gas to the internal channel, and a drug solution unit to supply a drug solution to the external channel. The lumen unit includes an inner coating including first and second inner surfaces, and micropores passing through the first and second inner surfaces, an outer coating including a first outer surface facing the second inner surface, a second outer surface positioned opposite the first outer surface, and a microneedle plate on the second outer surface, the internal channel surrounded by the first inner surface, and the external channel between the second inner surface and the first outer surface. The gas and the drug solution are mixed in the external channel to form a mixed drug solution, which is supplied to an outside through the microneedle plate.

This invention belongs to the field of pharmaceutical technology, specifically relating to a liquid formulation and method for inhibiting the degradation of pentetidine. The liquid formulation includes a drug solution sealed within a drug container and an ambient gas above the drug solution. The drug solution includes one or more of the following: an active pharmaceutical ingredient, pentetidine, and vitamin C and its salts; the ambient gas is primarily composed of non-oxidizing gases. This invention, by establishing a non-oxidizing gas environment in a liquid formulation system containing vitamin C or its salts and DTPA, can significantly reduce the oxidation and degradation rate of DTPA during storage, effectively inhibit the formation of new impurities derived from it, thereby improving the physicochemical stability of the formulation, extending its shelf life, and enhancing the safety and reliability of the product.

This invention relates to a dose regimen of radionuclides for use in the treatment of gastrointestinal cancers such as hepatocellular carcinoma (HCC) via brachytherapy, characterized by a two-component surgical sealant and / or adhesive such as tissue glue and a microsphere loaded with a radioisotope. The radioactive dose to be administered is in the range of 0.4 to 220 MBq, based on the size of the target tumor.